0001209191-20-011763.txt : 20200221
0001209191-20-011763.hdr.sgml : 20200221
20200221190543
ACCESSION NUMBER: 0001209191-20-011763
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200219
FILED AS OF DATE: 20200221
DATE AS OF CHANGE: 20200221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Cappel Markus J.
CENTRAL INDEX KEY: 0001422995
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35420
FILM NUMBER: 20641633
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ChemoCentryx, Inc.
CENTRAL INDEX KEY: 0001340652
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943254365
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
BUSINESS PHONE: 650-210-2900
MAIL ADDRESS:
STREET 1: 850 MAUDE AVENUE
CITY: MOUNTAIN VIEW
STATE: CA
ZIP: 94043
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2020-02-19
0
0001340652
ChemoCentryx, Inc.
CCXI
0001422995
Cappel Markus J.
C/O CHEMOCENTRYX, INC.
850 MAUDE AVENUE
MOUNTAIN VIEW
CA
94043
0
1
0
0
Chief Bus. Officer & Treasurer
Common Stock
2020-02-19
4
M
0
42631
8.19
A
118878
D
Common Stock
2020-02-19
4
S
0
41468
50.3374
D
77410
D
Common Stock
2020-02-19
4
S
0
1163
50.9943
D
76247
D
Stock Option (right to buy)
8.19
2020-02-19
4
M
0
42631
D
2025-02-23
Common Stock
42631
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $49.99 to $50.98 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
Reflects the weighted average sale price of the sales sold. The shares were sold in multiple trades at prices ranging from $50.99 to $51.00 per share. The Reporting Person will provide to the SEC staff, the issuer or a security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price.
This option was previously reported incorrectly as covering 42,901 shares.
As of February 19, 2020, and prior to this transaction, the exercised options were fully vested.
Not applicable.
/s/ Susan M. Kanaya, as Attorney-in-Fact
2020-02-21